Advice
Following a full submission
Anastrozole (Arimidex) is accepted for restricted use within NHS Scotland for the adjunctive treatment of early breast cancer in postmenopausal women with oestrogenreceptor positive disease who cannot take tamoxifen because of the presence of thrombophilic disorders or a past history of venous thromboembolic events, endometrial malignancy or undiagnosed vaginal bleeding. Treatment with anastrozole should be initiated by oncologists Tamoxifen continues to be the first line treatment for early breast cancer where it is not contra-indicated for the reasons above.
Download detailed advice22KB (PDF)
Medicine details
- Medicine name:
- Anastrozole (Arimidex®)
- SMC ID:
- 90/04
- Indication:
- Postmenopausal women with oestrogen receptor positive early invasive breast cancer
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 March 2004